We therefore tested the impact of Atrx deletion on sarcoma cell infection with an oncolytic herpesvirus variant of HSV-1 ordered from Imanis Life Sciences (Imanis oHSV) that has been modified to specifically target and destroy tumor cells (35). Here, ATRX is linked to neoplasm.